Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in the life sciences and healthcare sectors, primarily targeting opportunities in China but also considering ventures in other parts of East and South Asia. Lilly Asia Ventures seeks to invest in companies at various stages, from seed to later stages, with a preference for those showcasing strong management teams and innovative technologies or business models. The investment strategy emphasizes human therapeutics, medical technology, healthcare services, and broader life sciences. Typically, investments range from $5 million to $15 million per round, with an inclination towards acquiring minority stakes, usually under 20 percent. The firm aims to play an active role in its portfolio companies by seeking board seats or observation rights.
Comanche Biopharma is a biopharmaceutical company that develops siRNA therapy for the treatment of preeclampsia.
Alebund Pharmaceuticals
Series C in 2023
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
Bioyond Tech
Series A in 2023
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.
Neukio Biotherapeutics
Series A in 2022
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.
ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
IMPACT Therapeutics, Inc. is a Shanghai-based biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other severe diseases. Founded in 2009, the company is engaged in several innovative research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, and other novel DNA damage response agents, as well as Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights. The company's management team brings over four decades of combined experience in drug development and management, with expertise in pharmacology and biology, positioning the firm to advance its therapeutic offerings effectively.
GluBio Therapeutics
Series A in 2022
GluBio Pharmaceutical focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.
Pilot Bio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.
VIRTUE Diagnostics(Suzhou)Co.,Ltd. develops in vitro diagnostic platform. The company offers technology platforms including clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. VIRTUE Diagnostics(Suzhou)Co.,Ltd. was founded in 2019 and is based in Suzhou, China with a research and development office in Singapore.
ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.
Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics，pesticides，veterinary drugs, and new cosmetics.
Hopstem Biotechnology LLC specializes in neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells and human embryonic stem cells. It offers its technologies to promote biomedical research, diagnoses, and therapies of neurological and other disorders. The company was incorporated in 2019 and is headquartered in Houston, Texas.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.
Alebund Pharmaceuticals
Series B in 2021
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored.
It was founded in 2019 and is headquartered in San Diego, California.
LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.
Ionova Life Science Co., Ltd. operates as a biotechnology company. The company engages in discovery and development of novel medicine for cancer treatment. It focuses on oncology, including immune-oncology and target delivery. The company uses its in-house build discovery platform for the development purpose. Ionova Life Science Co., Ltd. was founded in 2016 and is based in Shenzhen, China with additional offices in Hong Kong, Macao and Greater Bay Area.
Abogen Biosciences
Series C in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Shanghai MediTrust Health Technology Co., Ltd. provides help to patients solve its medical expenses through financial insurance. The firm is based in Shanghai, China.
Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.
Zentera Therapeutics
Series B in 2021
Zentera Therapeutics is a biopharmaceutical company.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Pulnovo Medical specializes in the development and production of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on radiofrequency ablation technology, offering advanced solutions such as pulse radiofrequency ablation catheters and instruments. These pioneering products are designed to enhance the resilience and quality of life for patients suffering from pulmonary hypertension and heart failure. Pulnovo Medical holds global invention patents for its high-frequency ablation equipment and intravascular catheters, reflecting its commitment to advancing treatment methodologies in this critical area of healthcare.
Neukio Biotherapeutics
Angel Round in 2021
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
Synthekine Inc. is a biotechnology company focused on developing innovative cytokine therapies and immunotherapies for cancer and autoimmune disorders. Founded in 2018 and based in Menlo Park, California, the company leverages advanced platform technologies, including engineered partial agonists and orthogonal cell therapies, to create targeted treatments. Synthekine's notable innovations include the Synthekine Platform, which utilizes surrogate agonists instead of traditional mutant cytokines. The company's product pipeline features STK-009, an orthogonal ligand paired with SYNCAR-001, an engineered CAR-T therapy targeting CD-19, as well as STK-012, a partial agonist of IL-2. Synthekine's approach emphasizes safety and efficacy, utilizing immunological insights to guide the development of therapeutics that selectively modulate immune system pathways. Preclinical studies have indicated promising efficacy and tolerability for its lead programs, positioning Synthekine as a key player in the biotechnology landscape.
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.
It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Duality Biologics, founded in January 2020 by Dr. John Zhu, is a biotechnology company focused on developing innovative therapies for oncology and autoimmune diseases. The company is dedicated to addressing unmet medical needs through its internal pipeline, which includes nearly ten promising bispecific antibodies and Antibody-Drug Conjugate (ADC) candidates, several of which are in the investigational new drug (IND) stage. Duality Bio has established a next-generation ADC platform, backed by global intellectual property rights, to enhance drug development. The efficacy of this platform is demonstrated by multiple drug candidates currently under development, aimed at improving treatment outcomes for patients suffering from cancer and autoimmune disorders.
Duality Biologics, founded in January 2020 by Dr. John Zhu, is a biotechnology company focused on developing innovative therapies for oncology and autoimmune diseases. The company is dedicated to addressing unmet medical needs through its internal pipeline, which includes nearly ten promising bispecific antibodies and Antibody-Drug Conjugate (ADC) candidates, several of which are in the investigational new drug (IND) stage. Duality Bio has established a next-generation ADC platform, backed by global intellectual property rights, to enhance drug development. The efficacy of this platform is demonstrated by multiple drug candidates currently under development, aimed at improving treatment outcomes for patients suffering from cancer and autoimmune disorders.
Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.
Alebund Pharmaceuticals
Series B in 2021
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.
Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategic partnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.
Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, with a focus on developing innovative antibody-drug conjugate therapies for late-stage multiple myeloma and prostate cancer. The company was established based on technology exclusively licensed from the University of California, San Francisco, and developed in the laboratory of Dr. Bin Liu. Fortis Therapeutics aims to enhance treatment options for patients suffering from advanced adenocarcinoma and neuroendocrine cancer, leveraging its proprietary platform to create targeted therapies that improve clinical outcomes in late-stage cancer treatment.
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.
Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting oncology, metabolic diseases, and autoimmune diseases. Utilizing its proprietary CARD (Computer Accelerated Rational Discovery) platform, Regor integrates various scientific disciplines, including structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. This approach allows the company to efficiently produce both best-in-class and first-in-class therapeutic molecules. With a strong emphasis on scientific expertise, Regor Therapeutics aims to deliver clinically differentiated treatments that address unmet medical needs.
Beijing Targeting One Technology Co., Ltd. engages in the development and production of biomedical instruments, consumables, and in vitro diagnostic reagents for use in the fields of precision medicine, health management, and life science research. The company offers drop maker sample preparation apparatus, biochip readers, digital PCR supplies, ddPCR universal amplification reagents, micro-droplet generation and detection oils, genetic testing kits, and nucleic acid extraction reagents. Its digital PCR products have applications in the areas of transplant rejection monitoring, targeted sequencing, tumor liquid biopsy, and non-invasive prenatal screening. Beijing Targeting One Technology Co., Ltd. was founded in 2015 and is based in Beijing, China.
Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.
Terns Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns leverages its expertise in disease biology and medicinal chemistry to advance its drug pipeline. Notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company emphasizes a capital-efficient drug discovery model and has extensive clinical development capabilities in China, striving to bring innovative therapeutic candidates to address significant unmet medical needs both locally and globally.
MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company.
They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.
Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.
VIRTUE Diagnostics(Suzhou)Co.,Ltd. develops in vitro diagnostic platform. The company offers technology platforms including clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. VIRTUE Diagnostics(Suzhou)Co.,Ltd. was founded in 2019 and is based in Suzhou, China with a research and development office in Singapore.
dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.
IMPACT Therapeutics, Inc. is a Shanghai-based biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other severe diseases. Founded in 2009, the company is engaged in several innovative research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, and other novel DNA damage response agents, as well as Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights. The company's management team brings over four decades of combined experience in drug development and management, with expertise in pharmacology and biology, positioning the firm to advance its therapeutic offerings effectively.
CARsgen Therapeutics, Ltd., a clinical-stage immunotherapy company, develops and commercializes chimeric antigen receptor T-cell (CAR-T) therapeutics for treating cancers. It offers CAR-T Technology that directs T cells to recognize cancer cells based on expression of specific cell surface proteins to treat solid and hematologic tumors. The company’s CAR-T cells target the GPC3 receptor for the treatment of late-stage hepatocellular carcinoma (HCC, or liver cancer) and lung squamous cell carcinoma (a common type of lung cancer). CARsgen Therapeutics, Ltd. is based in Shanghai, China.
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing innovative cell therapies for cancer treatment. The company's lead product candidates include GC012F, a dual-targeted CAR-T therapy for multiple myeloma currently in Phase I trials; GC019F, which targets adult B cell acute lymphoblastic leukemia and is also in Phase I trials; and GC007F, aimed at B cell non-Hodgkin’s lymphoma, also in Phase I. Additionally, Gracell is developing GC027, a CAR-T candidate targeting adult T cell acute lymphoblastic leukemia, and GC007g, an allogeneic CAR-T therapy for relapsed or refractory B-ALL, both in Phase I trials. Beyond these, Gracell has a pipeline of earlier-stage product candidates targeting various cancers, including ovarian and breast cancer. Founded in 2017, Gracell Biotechnologies is committed to advancing cellular therapeutics to improve patient outcomes in hematological malignancies and solid tumors.
EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.
ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Sonoma Pharmaceuticals develops and produces stabilized hypochlorous acid (HOCl) products for various healthcare applications, including wound care, animal health, eye care, oral care, and dermatological conditions. The company offers a range of products such as Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription treatment for dermatoses; and Celacyn gel, which promotes healing of scars from surgical procedures and trauma. Additional offerings include SebuDerm for seborrhea management, Ceramax as a skin barrier cream, and Acuicyn for eye-related inflammation and cleanliness. Sonoma's Microcyn product line targets expedited healing of wounds and includes solutions for both human and animal care, addressing conditions such as hot spots and skin irritations. With over 100 commercialized products in 33 countries, Sonoma Pharmaceuticals aims to meet unmet medical needs while enhancing patient care and reducing healthcare costs. The company, originally known as Oculus Innovative Sciences, Inc., was rebranded in December 2016 and is headquartered in Woodstock, Georgia.
InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company is advancing a pipeline of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Notably, it is developing D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor, and is exploring combinations of its drugs with other immuno-oncology therapies, such as PD-1 antibodies, for various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with prior experience at major pharmaceutical companies like Merck and Schering-Plough, InventisBio aims to leverage their expertise in oncology and metabolic diseases to bring effective treatments to market.
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.
Dizal Pharmaceutical is a research-based biotechnology company dedicated to the discovery, development, and commercialization of first-in-class/best-in-class medicines.
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.
Legend Biotech is a biopharmaceutical company bringing impactful innovations in cell therapy, and accelerating the science. They are committed to improving the lives of patients worldwide. They are also steadfast in their goal to develop innovative cellular therapies that bring us closer to a cure. It develops cell therapies from discovery through commercialization.
Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.
Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategic partnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.
Alebund Pharmaceuticals
Series A in 2020
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.
Geneseeq Technology Inc., established in 2008 and based in Toronto, Canada, operates a clinical testing and diagnostic center specializing in next-generation sequencing (NGS) technologies. The company focuses on advancing precision medicine in cancer treatment by transforming patients' genomic information into actionable insights for healthcare providers. Geneseeq's laboratories have attained significant certifications, including those from China's National Center of Clinical Laboratories and the College of American Pathologists, ensuring high standards in clinical diagnostics. The company offers a range of personalized medical diagnostics and healthcare management services, including genetic screening and molecular diagnostics, aimed at enhancing the detection and treatment success of cancer.
“Peijia Medical” was established in early 2012, by returned oversea Chinese expert in professional medical device industry, providing R&D and production of interventional medical products. The company with register capital of RMB￥30 million is located in Suzhou Industrial Park, Suzhou city of Jiangsu Province. The city of Suzhou is famously named as "earthly paradise in China" and the Industrial Park beside Jinji Lake is called as “new paradise of venture capital investment”. The company covers an area of about 10000 sqm, within which laboratory and controlled environment room taking about 1800 sqm. The company has state of the art interior design with western high tech modern style infused with Suzhou oriental garden style. The office building, laboratory, and controlled environment production rooms are fully put into operation now.
ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.
dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.
Ionova Life Science Co., Ltd. operates as a biotechnology company. The company engages in discovery and development of novel medicine for cancer treatment. It focuses on oncology, including immune-oncology and target delivery. The company uses its in-house build discovery platform for the development purpose. Ionova Life Science Co., Ltd. was founded in 2016 and is based in Shenzhen, China with additional offices in Hong Kong, Macao and Greater Bay Area.
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus.
The company was founded in 2003 and is headquartered in San Diego, California.
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, that specializes in developing a diverse pipeline of novel biologic therapeutic candidates. The company is focused on addressing complex disease biology through its proprietary protein engineering methods, including a single-domain antibody platform. Its key candidates include INBRX-109, a multivalent agonist targeting death receptor 5 for solid tumors; INBRX-105, an antagonist of PD-L1 and conditional agonist of 4-1BB for PD-L1 expressing tumors; INBRX-101, an Fc-fusion protein aimed at alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting cluster of differentiation 47. Additionally, Inhibrx has preclinical programs such as INBRX-106 and INBRX-111, which focus on oncology and infectious diseases. The company has established collaborations with organizations like Celgene and bluebird bio and has received support from various granting agencies, including the NIH and CARB-X.
Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.
InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company is advancing a pipeline of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Notably, it is developing D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor, and is exploring combinations of its drugs with other immuno-oncology therapies, such as PD-1 antibodies, for various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with prior experience at major pharmaceutical companies like Merck and Schering-Plough, InventisBio aims to leverage their expertise in oncology and metabolic diseases to bring effective treatments to market.
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing innovative cell therapies for cancer treatment. The company's lead product candidates include GC012F, a dual-targeted CAR-T therapy for multiple myeloma currently in Phase I trials; GC019F, which targets adult B cell acute lymphoblastic leukemia and is also in Phase I trials; and GC007F, aimed at B cell non-Hodgkin’s lymphoma, also in Phase I. Additionally, Gracell is developing GC027, a CAR-T candidate targeting adult T cell acute lymphoblastic leukemia, and GC007g, an allogeneic CAR-T therapy for relapsed or refractory B-ALL, both in Phase I trials. Beyond these, Gracell has a pipeline of earlier-stage product candidates targeting various cancers, including ovarian and breast cancer. Founded in 2017, Gracell Biotechnologies is committed to advancing cellular therapeutics to improve patient outcomes in hematological malignancies and solid tumors.
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
NuVera Medical, Inc. operates an imaging platform for cardiovascular procedures. The product uses 4D ultrasound technology to process the images. The product can be used by healthcare specialists for Intracardiac Echocardiography. NuVera Medical, Inc. was founded in 2016 and is based in Campbell, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.